Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018 2019 2020

Details for Mechanism ID: 18215
Country/Region: Kenya
Year: 2017
Main Partner: Coptic Hospital
Main Partner Program: NA
Organizational Type: FBO
Funding Agency: HHS/CDC
Total Funding: $3,200,517 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: TB/HIV (HVTB) $199,023
Testing: HIV Testing and Counseling (HVCT) $144,881
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $41,514
Treatment: Adult Treatment (HTXS) $2,442,419
Treatment: Pediatric Treatment (PDTX) $372,680
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV <10, Female, Physical and/or Emotional Violence 2018 56
GEND_GBV <10, Female, Sexual Violence (Post-Rape Care) 2018 62
GEND_GBV <10, Male, Physical and/or Emotional Violence 2018 45
GEND_GBV <10, Male, Sexual Violence (Post-Rape Care) 2018 13
GEND_GBV 10-14, Female, Physical and/or Emotional Violence 2018 270
GEND_GBV 10-14, Female, Sexual Violence (Post-Rape Care) 2018 125
GEND_GBV 10-14, Male, Physical and/or Emotional Violence 2018 218
GEND_GBV 10-14, Male, Sexual Violence (Post-Rape Care) 2018 38
GEND_GBV 15-19, Female, Physical and/or Emotional Violence 2018 170
GEND_GBV 15-19, Female, Sexual Violence (Post-Rape Care) 2018 210
GEND_GBV 15-19, Male, Physical and/or Emotional Violence 2018 148
GEND_GBV 15-19, Male, Sexual Violence (Post-Rape Care) 2018 185
GEND_GBV 20-24, Female, Physical and/or Emotional Violence 2018 610
GEND_GBV 20-24, Female, Sexual Violence (Post-Rape Care) 2018 315
GEND_GBV 20-24, Male, Physical and/or Emotional Violence 2018 291
GEND_GBV 20-24, Male, Sexual Violence (Post-Rape Care) 2018 90
GEND_GBV 25-49, Female, Physical and/or Emotional Violence 2018 1,100
GEND_GBV 25-49, Female, Sexual Violence (Post-Rape Care) 2018 267
GEND_GBV 25-49, Male, Physical and/or Emotional Violence 2018 130
GEND_GBV 25-49, Male, Sexual Violence (Post-Rape Care) 2018 46
GEND_GBV 50+, Female, Physical and/or Emotional Violence 2018 120
GEND_GBV 50+, Female, Sexual Violence (Post-Rape Care) 2018 60
GEND_GBV 50+, Male, Physical and/or Emotional Violence 2018 10
GEND_GBV By PEP service provision (related to sexual violence services provided) 2018 564
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2018 3,168
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2018 1,411
GEND_GBV Number of people receiving post-GBV care 2018 4,579
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2018 31,198
HTS_TST Service Delivery Point (Facility) Index: <1, Negative 2018 13
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2018 58
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2018 21
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2018 18
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2018 82
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2018 59
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2018 122
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2018 102
HTS_TST Service Delivery Point (Facility) Index: 25-49, Female, Negative 2018 513
HTS_TST Service Delivery Point (Facility) Index: 25-49, Male, Negative 2018 357
HTS_TST Service Delivery Point (Facility) Index: 50+, Female, Negative 2018 88
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2018 80
HTS_TST Service Delivery Point (Facility) Inpatient: <1, Negative 2018 17
HTS_TST Service Delivery Point (Facility) Inpatient: 1-9, Negative 2018 95
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative 2018 33
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative 2018 30
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2018 127
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2018 94
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2018 195
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2018 162
HTS_TST Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative 2018 822
HTS_TST Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative 2018 572
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2018 142
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2018 131
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2018 830
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2018 294
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2018 243
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2018 1,114
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2018 828
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2018 1,714
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2018 1,444
HTS_TST Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative 2018 7,176
HTS_TST Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative 2018 5,003
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2018 1,247
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2018 1,145
HTS_TST Service Delivery Point (Facility) TB: <1, Negative 2018 5
HTS_TST Service Delivery Point (Facility) TB: 1-9, Negative 2018 24
HTS_TST Service Delivery Point (Facility) TB: 10-14, Female, Negative 2018 9
HTS_TST Service Delivery Point (Facility) TB: 10-14, Male, Negative 2018 7
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2018 34
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2018 21
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2018 49
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2018 41
HTS_TST Service Delivery Point (Facility) TB: 25-49, Female, Negative 2018 205
HTS_TST Service Delivery Point (Facility) TB: 25-49, Male, Negative 2018 143
HTS_TST Service Delivery Point (Facility) TB: 50+, Female, Negative 2018 36
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2018 31
HTS_TST Service Delivery Point (Facility) VCT: <1, Negative 2018 35
HTS_TST Service Delivery Point (Facility) VCT: 1-9, Negative 2018 178
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Female, Negative 2018 63
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Male, Negative 2018 52
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2018 238
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2018 178
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2018 367
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2018 309
HTS_TST Service Delivery Point (Facility) VCT: 25-49, Female, Negative 2018 1,538
HTS_TST Service Delivery Point (Facility) VCT: 25-49, Male, Negative 2018 1,072
HTS_TST Service Delivery Point (Facility) VCT: 50+, Female, Negative 2018 267
HTS_TST Service Delivery Point (Facility) VCT: 50+, Male, Negative 2018 244
HTS_TST Service Delivery Point (Facility)Other PITC: <1, Negative 2018 155
HTS_TST Sum of Test Result disaggregates 2018 925
HTS_TST_POS By Test Result: Positive 2018 925
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Female, Positive 2018 1
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Female, Positive 2018 2
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Male, Positive 2018 1
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2018 3
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2018 1
HTS_TST_POS Service Delivery Point (Facility) Index: 25-49, Female, Positive 2018 19
HTS_TST_POS Service Delivery Point (Facility) Index: 25-49, Male, Positive 2018 10
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Female, Positive 2018 5
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Male, Positive 2018 5
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 1-9, Positive 2018 1
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive 2018 1
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive 2018 1
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive 2018 4
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2018 7
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive 2018 3
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive 2018 31
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive 2018 17
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Female, Positive 2018 5
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Male, Positive 2018 6
HTS_TST_POS Service Delivery Point (Facility) Other PITC: <1, Positive 2018 2
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 1-9, Positive 2018 15
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive 2018 2
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive 2018 4
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2018 34
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2018 6
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2018 54
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2018 14
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive 2018 267
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive 2018 148
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2018 47
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2018 54
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Female, Positive 2018 1
HTS_TST_POS Service Delivery Point (Facility) TB: 25-49, Female, Positive 2018 8
HTS_TST_POS Service Delivery Point (Facility) TB: 25-49, Male, Positive 2018 4
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Female, Positive 2018 3
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Male, Positive 2018 3
HTS_TST_POS Service Delivery Point (Facility) VCT: 1-9, Positive 2018 2
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Male, Positive 2018 3
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Female, Positive 2018 6
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Male, Positive 2018 1
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2018 11
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2018 4
HTS_TST_POS Service Delivery Point (Facility) VCT: 25-49, Female, Positive 2018 56
HTS_TST_POS Service Delivery Point (Facility) VCT: 25-49, Male, Positive 2018 31
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Female, Positive 2018 11
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Male, Positive 2018 12
PMTCT_ART Already on ART at beginning of current pregnancy 2018 210
PMTCT_ART New on ART 2018 135
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2018 345
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 999
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2018 345
PMTCT_EID Number of infants with a negative virological test result between 2 and 12 months of birth 2018 28
PMTCT_EID Number of infants with a negative virological test result within 2 months of birth 2018 308
PMTCT_EID Number of infants with a positive virological test result between 2 and 12 months of birth 2018 5
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2018 4
PMTCT_STAT By Age (Numerator): 15-19 2018 12
PMTCT_STAT By Age (Numerator): 20-24 2018 181
PMTCT_STAT By Age (Numerator): 25-49 2018 806
PMTCT_STAT By Number of known positives: 15-19 2018 2
PMTCT_STAT By Number of known positives: 20-24 2018 13
PMTCT_STAT By Number of known positives: 25-49 2018 180
PMTCT_STAT By Number of new negative: 15-19 2018 10
PMTCT_STAT By Number of new negative: 20-24 2018 116
PMTCT_STAT By Number of new negative: 25-49 2018 510
PMTCT_STAT By Number of new positives: 20-24 2018 52
PMTCT_STAT By Number of new positives: 25-49 2018 116
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 999
PMTCT_STAT_den By Age (Denominator): <15-19 2018 12
PMTCT_STAT_den By Age (Denominator): 20-24 2018 181
PMTCT_STAT_den By Age (Denominator): 25-49 2018 806
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 4
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 81
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 4
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 72
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2018 161
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2018 161
TB_ART_den Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 4
TB_ART_den Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 81
TB_ART_den Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 4
TB_ART_den Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 72
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 4
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 122
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 4
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 108
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2018 238
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2018 250
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 4
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 129
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 4
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 113
TX_CURR Age/Sex: <1 2018 17
TX_CURR Age/Sex: <1-9 2018 225
TX_CURR Age/Sex: 10-14 Female 2018 171
TX_CURR Age/Sex: 10-14 Male 2018 188
TX_CURR Age/Sex: 15-19 Female 2018 195
TX_CURR Age/Sex: 15-19 Male 2018 210
TX_CURR Age/Sex: 20-24 Female 2018 264
TX_CURR Age/Sex: 20-24 Male 2018 123
TX_CURR Age/Sex: 25-49 Female 2018 7,857
TX_CURR Age/Sex: 25-49 Male 2018 3,228
TX_CURR Age/Sex: 50+ Female 2018 2,122
TX_CURR Age/Sex: 50+ Male 2018 1,895
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 16,495
TX_CURR Sum of age/sex disaggregates 2018 405
TX_NEW Breastfeeding status 2018 15
TX_NEW By Age/Sex: <1 2018 5
TX_NEW By Age/Sex: 1-9 2018 24
TX_NEW By Age/Sex: 10-14 Female 2018 21
TX_NEW By Age/Sex: 10-14 Male 2018 23
TX_NEW By Age/Sex: 15-19 Female 2018 42
TX_NEW By Age/Sex: 15-19 Male 2018 46
TX_NEW By Age/Sex: 20-24 Female 2018 58
TX_NEW By Age/Sex: 20-24 Male 2018 28
TX_NEW By Age/Sex: 25-49 Female 2018 1,714
TX_NEW By Age/Sex: 25-49 Male 2018 703
TX_NEW By Age/Sex: 50+ Female 2018 456
TX_NEW By Age/Sex: 50+ Male 2018 410
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 3,530
TX_NEW Pregnancy status 2018 135
TX_NEW Sum of Age/Sex disaggregates 2018 3,501
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 16,478
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 14,772
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 206
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 16
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 228
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 17
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 8,737
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 658
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 4,566
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 344
TX_PVLS Numerator: Indication: Routine 2018 13,737
TX_PVLS Numerator: Indication: Targeted 2018 1,035
TX_PVLS Numerator: Preg/BF by Indication: Breastfeeding Routine 2018 33
TX_PVLS Numerator: Preg/BF by Indication: Breastfeeding Targeted 2018 3
TX_PVLS Numerator: Preg/BF by Indication: Pregnant Routine 2018 290
TX_PVLS Numerator: Preg/BF by Indication: Pregnant Targeted 2018 21
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 256
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 19
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 286
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 22
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 9,708
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 731
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 5,074
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 382
TX_PVLS_den Denominator: Indication: Routine 2018 15,324
TX_PVLS_den Denominator: Indication: Targeted 2018 1,154
TX_PVLS_den Denominator: Preg/BF by Indication: Breastfeeding Routine 2018 36
TX_PVLS_den Denominator: Preg/BF by Indication: Breastfeeding Targeted 2018 3
TX_PVLS_den Denominator: Preg/BF by Indication: Pregnant Routine 2018 322
TX_PVLS_den Denominator: Preg/BF by Indication: Pregnant Targeted 2018 23
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 32
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 38
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 2,157
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 1,127
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 3,354
TX_RET Numerator by Status: Breastfeeding 2018 14
TX_RET Numerator by Status: Pregnant 2018 128
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 3,530
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 35
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 38
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 2,270
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 1,187
TX_RET_den Denominator by Status: Breastfeeding 2018 15
TX_RET_den Denominator by Status: Pregnant 2018 135
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2018 16,495
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2018 64
TX_TB Numerator: By Aggregated Age/Sex: <15, Female 2018 3
TX_TB Numerator: By Aggregated Age/Sex: <15, Male 2018 3
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2018 31
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2018 27
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2018 43
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2018 41
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2018 2,100
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2018 1,115
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2018 2,639
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert) 2018 165
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2018 495
TX_TB_den Denominator: By Screen Result: Negative 2018 13,196
TX_TB_den Denominator: By Screen Result: Positive 2018 3,299
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2018 3,299
Cross Cutting Budget Categories and Known Amounts Total: $1,880,000
Gender: Gender Based Violence (GBV) $80,000
GBV Prevention
Implementation
Capacity building
Post GBV Care
Implementation
Capacity building
Motor Vehicles: Purchased $200,000
Human Resources for Health $1,600,000